No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
Open Access
- 7 August 2009
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (2) , 207-213
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • ABCB1 genotype affects the pharmacokinetics and cholesterol‐lowering effects of simvastatin and atorvastatin.• The cholesterol‐lowering effect of fluvastatin has been associated with ABCB1 genotype, and pravastatin, lovastatin, lovastatin acid, and rosuvastatin are substrates of ABCB1.• However, it is not known whether ABCB1 genotype affects the pharmacokinetics of fluvastatin, pravastatin, lovastatin, or rosuvastatin. WHAT THIS STUDY ADDS • ABCB1 c.1236C‐c.2677G‐c.3435C and c.1236T‐c.2677T‐c.3435T haplotypes have no significant effects on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, or rosuvastatin.AIMS: This study aimed to investigate possible effects of ABCB1 genotype on fluvastatin, pravastatin, lovastatin, and rosuvastatin pharmacokinetics.METHODS: In a fixed‐order crossover study, 10 healthy volunteers with the ABCB1 c.1236C/C‐c.2677G/G‐c.3435C/C (CGC/CGC) genotype and 10 with the c.1236T/T‐c.2677T/T‐c.3435T/T (TTT/TTT) genotype ingested a single 20‐mg dose of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Plasma fluvastatin, pravastatin, and lovastatin concentrations were measured up to 12 h and plasma and urine rosuvastatin concentrations up to 48 and 24 h, respectively.RESULTS: The ABCB1 genotype had no significant effect on the pharmacokinetics of any of the investigated statins. The geometric mean ratio (95% confidence interval) of the area under the plasma concentration–time curve from 0 h to infinity (AUC0–∞) in participants with the TTT/TTT genotype to that in those with the CGC/CGC genotype was 0.96 (0.77, 1.20; P= 0.737) for fluvastatin, 0.92 (0.53, 1.62; P= 0.772) for pravastatin, 0.83 (0.36, 1.90; P= 0.644) for lovastatin, 1.25 (0.72, 2.17; P= 0.400) for lovastatin acid, and 1.10 (0.73, 1.65; P= 0.626) for rosuvastatin. The AUC0–∞ of lovastatin acid correlated significantly with that of rosuvastatin (r= 0.570, P= 0.009), but none of the other AUC0–∞ pairs showed a significant correlation.CONCLUSIONS: These data suggest that the ABCB1 c.1236C‐c.2677G‐c.3435C and c.1236T‐c.2677T‐c.3435T haplotypes play no significant role in the interindividual variability in the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.Keywords
This publication has 35 references indexed in Scilit:
- PXR: A Xenobiotic Receptor of Diverse Function Implicated in PharmacogeneticsPharmacogenomics, 2008
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- Pharmacogenomics and Drug ToxicityNew England Journal of Medicine, 2008
- Shift of statin use towards the elderly in 1995−2005: a nation‐wide register study in FinlandBritish Journal of Clinical Pharmacology, 2008
- An improved and fully validated LC–MS/MS method for the simultaneous quantification of simvastatin and simvastatin acid in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2008
- Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphismsPharmacogenetics and Genomics, 2008
- Pharmacogenomics of statin responseCurrent Opinion in Lipidology, 2007
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- Lipid-lowering response to statins is affected by CYP3A5 polymorphismPharmacogenetics, 2004
- Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific mannerThe American Journal of Cardiology, 2004